Summit Therapeutics (SMMT) to Release Earnings on Wednesday

Summit Therapeutics (NASDAQ:SMMT) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Summit Therapeutics (NASDAQ:SMMT) last announced its earnings results on Tuesday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Performance

NASDAQ:SMMT opened at $21.26 on Monday. The firm has a market cap of $15.40 billion, a price-to-earnings ratio of -92.43 and a beta of -0.97. The firm has a 50-day moving average price of $19.24 and a two-hundred day moving average price of $11.40. Summit Therapeutics has a 52 week low of $1.64 and a 52 week high of $33.89.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SMMT shares. Citigroup cut Summit Therapeutics from a “buy” rating to a “neutral” rating and upped their price target for the company from $19.00 to $23.00 in a research report on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Summit Therapeutics in a research note on Friday, October 4th. Finally, Stifel Nicolaus upped their price objective on shares of Summit Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.